ReviewFrontiers in immunology2026
Ferroptosis: a promising therapeutic target for periodontitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network pharmacology, molecular docking, and experimental validation of the mechanisms of Withaferin a in treating periodontitis.Clinical oral investigations · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a chronic inflammatory disease driven by dysbiotic biofilm and abnormal host adaptive immune responses, characterized by irreversible destruction of periodontal tissues. Recent studies indicate that ferroptosis-a form of iron-dependent lipid peroxidation-mediated cell death-is not a passive outcome of the disease process but rather an important active inducer and pathological amplifier in the development of periodontitis. This review synthesizes existing evidence to propose that ferroptosis acts as an important regulatory node within the pathological network of periodontitis, impairs epithelial barrier function, suppresses osteoblast differentiation and function, and amplifies pro-inflammatory signaling pathways through cell-type-specific mechanisms. Furthermore, ferroptosis exhibits complex cross-regulation with other cell death pathways (e.g., pyroptosis, apoptosis, autophagy), collectively forming a self-amplifying vicious cycle that persistently drives chronic inflammation and tissue destruction. Although iron death-targeting interventions, including iron chelators, GPX4 agonists, lipid peroxidation scavengers, natural bioactive compounds (e.g., curcumin, resveratrol), and nanodelivery systems, show promise in preclinical studies, the cell type specificity and context dependency of ferroptosis pose critical challenges for precise intervention. Therefore, this review positions ferroptosis as a pivotal node in the regulatory network of periodontal cell death, advocating for the development of stage-specific and cell-type-specific targeted strategies. This signifies a paradigm shift in periodontal therapy, transitioning from traditional antimicrobial approaches toward host-centered precision periodontal medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.